Trial Profile

Randomized, single-blind study of first component of the Russian Sputnik V vaccine against coronavirus (Sputnik Light vaccine based on human adenovirus serotype 26) and vaccines produced by AstraZeneca, Sinopharm and Moderna

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary)
Indications COVID 2019 infections
Focus Adverse reactions

11 Aug 2021 New trial record
05 Aug 2021 According to Russian Direct Investment Fund, RDIF is a partner of the study
04 Aug 2021 Results (n=121)published in the Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com